Analyst Price Targets — TCRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 7, 2025 10:18 am | — | Barclays | $3.00 | $1.98 | TheFly | TScan Therapeutics price target lowered to $3 from $14 at Barclays |
| May 16, 2024 6:44 am | Justin Zelin | BTIG | $12.00 | $8.93 | TheFly | TScan Therapeutics initiated with a Buy at BTIG |
Latest News for TCRX
Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing process
WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a hybrid presentation followed by an analyst-led Q&A session at the TD Cowen 46th Annual Health Care…
TScan Therapeutics, Inc. (NASDAQ: TCRX - Get Free Report) has received an average rating of "Hold" from the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have given a buy recommendation to
Treatment arm continues to demonstrate favorable relapse-free survival (HR=0. 50; p=0. 23) and overall survival (HR=0. 61; p=0. 52) 3/3 (100%) of TSC-101-treated patients who reached two-year follow-up remained relapse-free vs.
/PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TCRX.
U.S. House Trading
No House trades found for TCRX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.